GT Apeiron Therapeutics
Dr. Xiao-hui Gu is the Senior Vice President of Chemistry at Apeiron Therapeutics. Dr. Gu has over 20 years of research and development experience in the pharmaceutical industry. Dr. Gu has been engaged in the research, development, and management of novel drugs at several pharmaceutical companies and CROs, including X-Ceptor, Exelixis, ShangPharma, Otsuka, and Pharmaron. Prior to joining GT Apeiron, Dr. Gu was Senior Director of R&D at the Simcere Pharmaceutical Group. Dr. Gu received his doctorate degree in organic chemistry from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. He completed his postdoctoral training at the National Institutes of Health (NIH) with Dr. Kenner C. Rice as well as at McLean Hospital, Harvard Medical School, with Professor John L. Neumeyer.
GT Apeiron Therapeutics
Apeiron Therapeutics intends to develop breakthrough investigational medicines by harnessing the power of artificial intelligence which drastically increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials.